Dillan DiNardo @DillanDiNardo Sep 5, 2024 1/ We're thrilled to announce we've received both FDA & EMA approval to beg...
A social announcement claims both FDA and EMA approval to begin human trials of a neurotechnology platform intended to 'design altered states'—framed as a step beyond traditional psychedelics toward precision design of mood, cognition, and perception. Related posts hint at imminent double‑blind 5‑MeO clinical data and broader methodological work on measuring psychoactive effects. Key identifiers (company, trial registry number, indications, endpoints, and supporting filings) are not provided, which limits tradable signal strength.
Linked assets
EMA is referenced in the announcement as having granted approval to begin human trials for the described neurotech program. No public company ticker, clinical trial identifiers, or regulatory filings were linked to validate the claim.
Social post claims FDA and EMA approval to begin human trials of a neurotech platform for designing altered states; no sponsor or trial identifiers provided.
Dillan DiNardo tweeted that both FDA and EMA approvals were received to begin human trials for a neurotechnology platform aimed at precision design of mood, cognition, and perception, positioned as beyond traditional psychedelics. The claim references regulatory approval (EMA) but supplies no company name, trial registry numbers, indications, endpoints, or supporting documentation. Because the post names no public issuer or filings, the actionable link to any public equity (including EMA as an acronym reference) is unverified and should be treated cautiously until independent regulatory or sponsor documentation is produced.
Source proof
Source proof: Supported source proof | 2 extracted claims | 1 directional asset | 1 supporting author | headline-like title review
Primary sources are social posts by Dillan DiNardo and others. They state FDA and EMA approval to start human trials and mention imminent controlled 5‑MeO data. The posts do not attach regulatory letters, trial identifiers (e.g., NCT numbers), sponsor names, or peer‑reviewed data. Without corroborating documents or registries, the claims remain unvalidated.
Post hints at an imminent (tomorrow) release of the first controlled double‑blind clinical data for a “next 5‑MeO” (5‑MeO‑DMT or related) psychedelic program. No company, indication, trial phase, or endpoint details are provided, so actionability is limited; however it suggests a near‑term biotech/psychedelics catalyst that could move the most directly exposed public names.
Discussion about improving measurement/labeling of psychoactive effects by cross‑mapping validated psychometrics to MedDRA adverse events (AEs), plus an internal ontology and semantic embedding spaces. This is conceptual/product‑methodology commentary (pharmacovigilance / clinical data / AI semantics) with no explicit company, catalyst, or security mentioned.
A single social post claims completion of a first‑in‑human trial for a neurotech platform to “design mental states” at a molecular level, framing it as a sequel to psychedelics and a potential new class of psychoactive/mental‑state therapeutics. No company name, trial details, indication, endpoints, regulator, or funding are provided, so the content is not directly tradable without identifying the developer and validating the claim.
A tweet claims the author’s organization received both FDA and EMA approval to begin human trials for a neurotech platform aimed at “precision design” of altered states (mood/cognition/perception), positioning it as beyond traditional psychedelics.
Supporting authors
Content originates from one primary author (Dillan DiNardo) and related social posts by other contributors discussed in linked events. No institutional press release, regulatory docket, or clinical registry entry is cited.
Unlock full thesis monitoring
Monitor for corroborating evidence: regulatory filings, clinicaltrial.gov/EMA registry entries, company press releases, sponsor identification, and primary trial data. Do not assume public‑company exposure until a sponsor or company name and verifiable filings are identified.